Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip World Congress 2020

Organ-on-a-Chip World Congress 2020 Agenda

Print Agenda

Monday, 28 September 2020


Tissue Organoids for Disease Modeling
Shay Soker, Professor of Regenerative Medicine and Chief Science Program Officer, Wake Forest Institute for Regenerative Medicine, United States of America

Traditional in vitro two dimensional (2D) cell cultures fail to recapitulate the microenvironment of in vivo tissues. They have three major differences from native tissue microenvironments: substrate topography, substrate stiffness, and most importantly, a 2D rather than three dimensional (3D) architecture. In contrast, 3D human tissue organoids replicate native tissue structure and function and thus are superior to traditional 2D cultures and animal models. These organoids can be studied in vitro for several weeks to allow intensive investigations. Besides their advantages in drug toxicity testing and for development of new drugs, the human tissue organoid platform serves as a model system to explore human tissue development and disease. Our recent research was focused on the use of human tissue organoids to study liver development and congenital diseases as well as other common diseases such as tissue fibrosis and cancer. Altogether our human tissue organoids system can be used for modeling of a wide verity of diseases and develop new personalized/precision medicine applications.


Steven C. GeorgeKeynote Presentation

“Bone Marrow-on-a-Chip”: Replicating Hematopoiesis and Investigating the Impact of Ionizing Radiation
Steven C. George, Professor and Chair, University of California, Davis, United States of America

Tissue engineering holds enormous potential to not only replace or restore function to a wide range of tissues, but also to capture and control 3D physiology in vitro (e.g., microphysiological systems or “organ-on-a-chip” technology).  The latter has important applications in the fields of drug development, toxicity screening, modeling tumor metastasis, and repairing damaged cardiac (heart) muscle. In order to replicate the complex 3D arrangement of cells and extracellular matrix (ECM), new human microphysiological systems must be developed.  The past decade has brought tremendous advances in our understanding of stem cell technology and microfabrication producing a rich environment to create an array of “organ-on-a-chip” designs.  Over the past six years we have developed novel microfluidic-based systems of 3D human microtissues (~ 1 mm3) that contain features such as perfused human microvessels, primary human cancer, mouse tumor organoids, stem cells, and spatiotemporal control of oxygen.  The technologies are part of two early start-up companies, Kino Biosciences and Immunovalent Therapeutics, based in Irvine, CA and St. Louis, MO.  This seminar will describe our approach to create a 3D in vitro model of human bone marrow to assess the impact of ionizing radiation.


Ali KhademhosseiniKeynote Presentation

Title to be Confirmed.
Ali Khademhosseini, Professor, Department of Bioengineering, Department of Radiology, Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, United States of America


Veryst Engineering, LLCModeling and Simulation of Microfluidic Organ-on-a-Chip Devices
Matthew Hancock, Managing Engineer, Veryst Engineering, LLC

Modeling and simulation are key components of the engineering development process, providing a rational, systematic method to engineer and optimize products and dramatically accelerate the development cycle over a pure intuition-driven, empirical testing approach. Modeling and simulation help to identify key parameters related to product performance (“what to try”) as well as insignificant parameters or conditions related to poor outcomes (“what not to try”). For microfluidic organ-on-chip devices, modeling and simulation can inform the design and integration of common components such as mixers, micropumps, manifolds, and channel networks. Modeling and simulation may also be used to estimate a range of processes occurring within the fluid bulk and near cells, including shear stresses, transport of nutrients and waste, chemical reactions, heat transfer, and surface tension & wetting effects. I will discuss how an array of modeling tools such as scaling arguments, analytical formulas, and finite element simulations may be leveraged to address these microfluidic organ-on-a-chip device development issues. I will also work through a few examples in detail.


Title to be Confirmed.
Murat Cirit, CEO & Co-Founder, Javelin Biotech, United States of America


Roger KammKeynote Presentation

Metastasis on a Chip: Effects of Intravascular and Transendothelial Flow
Roger Kamm, Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT), United States of America

Circulating tumor cells (CTC) experience a hostile environment due circulating immune cells and the forces combined with vascular shear stress and pressure gradients.  In this study, we examine flow effects on CTC adhesion, migration and transendothelial migration.  Many CTCs fail to survive the voyage from the primary tumor to the metastatic site, and die before they can initiate a new tumor.  Others not only survive, but enter into the tissue where some fraction proliferate and spread.  We studied the effects of vascular flows, both intravascular (IVF) and transendothelial (TEF) on tumor cell adhesion, migration and transendothelial migration with the goal of better understanding how flow either promotes or impedes metastasis.  Our results show that CTCs migrate or are dragged in the direction of flow prior to trans-endothelial migration.  We also observe enhanced potential for TEM due to IVF.  TEF, on the other hand, has little effect on either migration along the luminal surface of the endothelium or the propensity to undergo trans-endothelial migration, but hastens the process once initiated.  Moreover, TEF increased the migration speed of tumor cells post-extravasation, and caused the cells to remain close to the outer endothelial surface. In summary, both types of flow tend to promote a pro-metastatic phenotype.


Nancy AllbrittonKeynote Presentation

Microengineering a Physiologic Colon Replica
Nancy Allbritton, Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering, University of Washington in Seattle, United States of America

Organ-on-chips are miniaturized devices that arrange living cells to simulate functional subunits of tissues and organs. These microdevices provide exquisite control of tissue microenvironment for the investigation of organ-level physiology and disease. A 3D polarized epithelium using primary human gastrointestinal stem cells was developed to fully recapitulate gastrointestinal epithelial architecture and physiology. A planar monolayer comprised of stem/proliferative and differentiated primary cells is cultured on a shaped hydrogel scaffold with an array of crypt-like structures replicating the intestinal architecture. These planar layers display physiologic drug transport and metabolism and immunologically appropriate responses. Facile co-culture with other cell types such as immune cells or myofibrolasts is readily achieved. A dense mucus layer is formed on the luminal epithelial surface that is impermeable to bacteria and acts a barrier to toxins. The in vitro mucus has remarkably similar in its biophysical properties to that produced in vivo. Imposition of chemical gradients across the crypt long axis yields a polarized epithelium with a stem-cell niche and differentiated cell zone. The stem cells proliferate, migrate and differentiate along the crypt axis as they do in vivo. An oxygen gradient across the tissue mimic permits luminal culture of anaerobic bacteria while maintaining an oxygenated stem cell niche. This in vitro human colon crypt array replicates the architecture, luminal accessibility, tissue polarity, cell migration, and cellular responses of in vivo intestinal crypts. This bioanalytical platform is envisioned as a next-generation system for assay of microbiome-behavior, drug-delivery and toxin-interactions with the intestinal epithelia.


Microfluidic ChipShopIt’s the Economy – Industrial Aspects of Organ-on-a-Chip Device Manufacturing
Holger Becker, Chief Scientific Officer, Microfluidic ChipShop

While academic activities in the organ-on-a-chip field have multiplied in recent years, it becomes apparent that translating academic results into commercially viable products can be challenging. This is even more true for such devices which require a generically multidisciplinary approach, combining application know-how with surface chemistry, microfabrication and materials technology. In this presentation, we will give an overview over available solutions for such products and explain classical pitfalls on the way from the academic laboratory bench to an industrial product.


Title to be Confirmed.
Gary Gintant, Senior Research Fellow, Abbvie, United States of America


John WikswoKeynote Presentation

The Biological and Technical Challenges of MicroPhysiological Systems: Past, Present, and Future
John Wikswo, Gordon A. Cain University Professor, A.B. Learned Professor of Living State Physics; Founding Director, Vanderbilt Institute for Integrative Biosystems, Vanderbilt University, United States of America

We must celebrate a decade of microphysiological systems (MPS) research in the US that began with the 2010 papers on Shuler’s and Esch’s body on a chip and the Huh’s, Ingber’s, and colleagues’ lung on a chip, received critical funding impulses from FDA, DARPA, NIH, and DTRA, and was forged by NIH/NCATS into a large, functional community. NASA, EPA, and other agencies are expanding the scope of research. Academic groups are publishing more than a thousand papers a year and there are more than a dozen companies in the US and Europe offering single- and multiple-organ chips and platforms. Now would be a good time to assess how well MPS researchers have addressed the engineering challenges for instrumenting and controlling integrated organ-on-chip systems that I enumerated in 2013, compare the capabilities and weaknesses of organoids and tissue chips, and assess the current and future value of coupled organ systems. As we address the early challenges, some remain and new ones appear: How do we obtain or create the appropriate cells? How do we build low-cost, disposable pumps and valves to perfuse and couple organ chips? What are our alternatives to PDMS? How do we acquire and analyze the data required for quantitative characterization of our MPS models? How do we recapitulate the adaptive immune system? What are our capabilities to control, rather than just observe, MPS models? How do we address the complexity, for example, of the neurohumeral connections between the microbiome-gut-immune-liver-brain axis in development, health, aging, and disease and with exposure to pathogens and toxins? All of these technologies should help us close the hermeneutic circle of biology, particularly now that we are within striking distance of being able to create robot scientists that can operate 10,000 independent, parallel MPS models and use optimum design-of-experiment techniques to generate and test hypotheses about biological regulation. The second MPS decade should be productive and exciting.


Michael ShulerKeynote Presentation

Body on a Chip: Human Microscale Models for Drug Development
Michael Shuler, Samuel B. Eckert Professor of Engineering, Cornell University, President & CEO, Hesperos, Inc., United States of America

Integrated, multi-organ microphysiological systems (MPS) based on human tissues (also known as “human-on-a-chip”) could be important tools to improve the selection of drug candidates most likely to earn regulatory approval from clinical trials. Such microscale systems combine organized human tissues with the techniques of microfabrication based on PBPK (Physiologically Based Pharmacokinetic) models.  I will describe such systems being constructed at Hesperos and at Cornell. They are “self-contained” in that they can operate independently and do not require external pumps as is the case with many other microphysiological systems. They are “low cost”, in part, because of the simplicity and reliability of operation. They maintain a ratio of fluid (blood surrogate) to cells that is more physiologic than in many other in vitro systems allowing the observation of the effects of not only drugs but their metabolites. While systems can be sampled to measure the concentrations of drugs, metabolites, or biomarkers, they also can be interrogated in situ for functional responses such as electrical activity, force generation, or integrity of barrier function. Operation up to 28 days has been achieved allowing observation of both acute and chronic responses with serum free media.  We have worked with various combinations of internal organ modules (liver, fat, neuromuscular junction, skeletal muscle, cardiac, bone marrow, blood vessels and brain) and barrier tissues (eg skin, GI tract, blood brain barrier, lung, and kidney). We have achieved unidirectional flow in a pumpless system which is important for mimicking the response of  vascular tissues and constructed blood brain mimics with human in vitro like characteristics. The use of microelectrode arrays to monitor electrically active tissues (cardiac and neuronal) and micro cantilevers (muscle) have been demonstrated. While most systems use 5 or fewer organ modules, we have demonstrated that a 13 “organ” compartment device can be constructed demonstrating the potential to address a wide range of problems in pharmacology and toxicology in a low cost system. Most importantly these technical advances allow prediction of both a drug’s potential efficacy and toxicity (side-effects) in pre-clinical studies and have been applied to circulating immune cells.


Kevin HealyKeynote Presentation

Exploiting Cardiac Microphysiological Systems For COVID-19 Drug Screening
Kevin Healy, Jan Fandrianto and Selfia Halim Distinguished Professorship in Engineering, University of California, Berkeley, United States of America

Our work has emphasized creating both healthy and diseased cardiac and liver microphysiological systems (MPS) or ‘organ chips’, to address the costly and inefficient drug discovery process. While MPS are poised to disrupt the drug development process and significantly reduce the cost of bringing a new drug candidate to market, the technology is more robust and creates a whole new paradigm in how to conduct safety pharmacology science, and advances medicine in revolutionary ways. An emerging use of MPS is in the evaluation of repurposed drugs to treat COVID-19. While repurposed drugs are typically FDA-approved for monotherapy, most have not been tested in polytherapy with  anti-inflammatory or antibiotic medications typically employed as part of intensive care protocols. Since COVID-19 patient morbidity is highly correlated with myocardial injury, independent of pre-existing cardiovascular disease, this presentation will address examples of exploiting our human cardiac MPS as unique testbeds for rapidly assessing the cardiac liability of polytherapy of repurposed COVID-19 drugs. Preclinical data generated will inform clinical trial design for polytherapies for COVID-19 patients, particularly regarding risks of potential drug-drug interactions or identifying appropriate exclusion criteria, monitoring strategies, and dose adjustments to minimize cardiac liabilities.

Agenda is not currently available
Add to Calendar ▼2020-09-28 00:00:002020-09-30 00:00:00Europe/LondonOrgan-on-a-Chip World Congress 2020Organ-on-a-Chip World Congress 2020 in Coronado Island, CaliforniaCoronado Island,